我要投票 衡欣在益生菌行业中的票数:410
· 外 推 电 报 ·
2025-08-25 00:39:59 星期一

【衡欣是哪个国家的品牌?】

衡欣是什么牌子?「衡欣」是 哈尔滨美华生物技术股份有限公司 旗下著名品牌。该品牌发源于黑龙江省哈尔滨市,在2002年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力衡欣品牌出海!将品牌入驻外推网,定制衡欣品牌推广信息,可以显著提高衡欣产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

专业从事微生态制剂、功能性食品、乳制品、乳制品添加剂等生物技术产品领域,国内规模较大的益生菌研发、生产、经营的企业


哈尔滨美华生物技术股份有限公司(以下简称哈美华生物)创建于2002年初,是专注于研发和生产微生态制剂、改善人类健康为己任的股份制企业。哈美华生物生产基地坐落于中国哈尔滨市的西部,这里气候寒冷,空气清爽,远离市区,非常适宜微生态制品的研发、生产。 哈美华生物占地面积3万平方米,建筑面积近1万平方米;具有高起点、高标准的多条生产线,是目前国内规模化、专业化的大型益生菌研发、生产企业。 哈美华生物实行董事会领导下的总经理负责制,建立了完善的企业职能体系和管理制度。生产管理严格按质量体系认证标准规范运行,从而形成了内部质量保障体系。

公司与中科院微生物研究所、中国农大、东北农大、哈尔滨商大食品学院及北京林大生物工程学院等国内科研院校建立了技术合作平台,在生物工程、工艺技术领域密切合作、共同研发,为公司的微生物制品技术持续发展和不断升级奠定了雄厚基础。公司还专门成立了生物工程技术研究所,从事微生态制剂、功能性食品、乳制品、乳制品添加剂等生物技术产品的研发和技术更新,不断为中国自有微生物技术的发展和持续成长开拓创新。 公司还提供可广泛用于乳品工业、保健食品工业、食品和医药企业使用的乳糖酶、稳定剂等系列高科技产品。公司将持续不断的努力研发新品,使我们的产品为广大客户带来更佳的效益。 哈美华生物始终坚持“以人才为核心,技术为保障,提供高标准的优质产品和专业的解决方案,以满足客户发展为目标,以造福人类健康为己任”。


英文翻译:Harbin Meihua Biotechnology Co., Ltd. (hereinafter referred to as hamihua Biology), a large-scale probiotic R & D, production and operation enterprise in China, was founded in early 2002. It is a share dedicated to R & D and production of microecological preparations and improvement of human health Share enterprises. Harbin Meihua biological production base is located in the west of Harbin City, China. The climate here is cold and the air is fresh. It is far away from the city. It is very suitable for the research, development and production of micro ecological products. Hami bio occupies an area of 30000 square meters and a building area of nearly 10000 square meters. It has a high starting point and high standard production lines, and is a large-scale and specialized probiotic research and development and production enterprise in China. Hami bio implements the general manager responsibility system under the leadership of the board of directors, and has established a perfect enterprise function system and management system. Production management operates in strict accordance with the quality system certification standards, thus forming an internal quality assurance system. The company has established a technical cooperation platform with the Institute of Microbiology of Chinese Academy of Sciences, China Agricultural University, Northeast Agricultural University, Harbin Commercial University Food College, Beijing Forestry University Bioengineering College and other domestic scientific research institutions, and has closely cooperated and jointly developed in the fields of bioengineering and process technology, laying a solid foundation for the continuous development and upgrading of the company's microbial products technology. The company has also set up a bioengineering technology research institute, which is engaged in the R & D and technology update of biotechnology products such as microecological agents, functional foods, dairy products, dairy additives, etc., and constantly develops and innovates for the development and sustainable growth of China's own microbial technology. The company also provides a series of high-tech products, such as lactase and stabilizer, which can be widely used in dairy industry, health food industry, food and pharmaceutical enterprises. The company will continue to work hard to develop new products, so that our products for our customers to bring better benefits. Hami bio always adheres to the principle of "taking talents as the core, technology as the guarantee, providing high standard high-quality products and professional solutions, aiming at satisfying the development of customers and benefiting human health".

本文链接: https://www.waitui.com/brand/572600437.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

格林美:筹划发行H股股票并在香港联交所上市

36氪获悉,格林美发布公告,经充分研究论证,董事会同意公司发行H股股票并在香港联合交易所有限公司(简称“香港联交所”)主板挂牌上市。公司将充分考虑现有股东的利益和境内外资本市场的情况,在股东会决议有效期内(即经公司股东会审议通过之日起24个月或同意延长的其他期限)选择适当的时机和发行窗口完成本次发行上市。截至目前,公司正积极与相关中介机构就本次发行上市的相关工作进行商讨,除本次董事会、监事会审议通过的相关议案外,其他关于本次发行上市的具体细节尚未最终确定。

40分钟前

中信证券:预计未来中国前列腺癌RDC诊疗市场将超100亿元

36氪获悉,中信证券研报表示,创新核药RDC有望解决目前前列腺癌诊疗过程中检测负担大、疗效有限等未被满足临床需求,改变前列腺癌诊疗范式,实现诊疗一体化,提高患者依从性和生存期。目前中国尚无任何RDC上市,市场呈现蓝海状态,海外前列腺癌RDC诊疗产品在2021年上市,2024年市场已接近30亿美元,充分验证了其巨大的商业价值。中信证券认为中国有望复刻海外前列腺癌RDC诊疗市场发展路径,预计未来中国前列腺癌RDC诊疗市场将超100亿元,市场呈现高速增长状态。该行业关键点为核素、配体分子形态、生产配送能力,建议关注在上述条件具有优势的公司。

40分钟前

​锡业股份:上半年净利润10.62亿元,同比增长32.76%

36氪获悉,锡业股份披露2025年半年报,上半年实现营业收入210.93亿元,同比增长12.35%;归属于上市公司股东的净利润10.62亿元,同比增长32.76%;基本每股收益0.626元。

40分钟前

亚世光电:上半年净利润538.04万元,同比下降36.21%

36氪获悉,亚世光电披露2025年半年报,上半年实现营业收入4.32亿元,同比增长30.01%;归属于上市公司股东的净利润538.04万元,同比下降36.21%;基本每股收益0.0331元。

40分钟前

金螳螂:上半年净利润3.58亿元,同比增长3.95%

36氪获悉,金螳螂披露2025年半年报,上半年实现营业收入95.28亿元,同比增长2.49%;归属于上市公司股东的净利润3.58亿元,同比增长3.95%;基本每股收益0.1348元。

40分钟前

本页详细列出关于衡欣的品牌信息,含品牌所属公司介绍,衡欣所处行业的品牌地位及优势。
咨询